Innate Pharma : Des développements cliniques qui continuent d’avancer ; Arrêt de la collaboration avec Takeda sans impact sur nos chiffres
>Horizon cash à fin 2025 - Innate Pharma publie ce matin ses résultats au titre du premier semestre 2024. Les produits opérationnels sur la période ressortent à 12.3 M€ (vs 40.2 M€) dont i / 8.3 M€ provenant de ses accords de développement principalement avec AstraZeneca et Sanofi (vs 27.1 M€ en 2023 bénéficiant de la réception d’un paiement initial de 25 M€ de Sanofi) et ii / 4.1 M€ de financement public de la recherche (contre 4.9 M€ en 2023). Les charges opérationn...Innate Pharma S.A. is a biopharmaceutical Company developing immunotherapy drugs for cancer and inflammatory diseases. Co. specializes in the development of new monoclonal antibodies targeting receptors and pathways controlling the activation of innate immunity cells. Also, Co. has three product-candidates resulting from its research platform are being tested in clinical trials; two of these by Co.'s partners, Bristol-Myers Squibb and Novo Nordisk A/S. Co. focuses on immunopharmacology and antibody technology. Co. has a panel of molecular and cellular assays and in vivo models for assessing the pharmacodynamics, the pharmacotoxicology and efficacy of drug candidates.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.